Neuroreport · 2003 · 65 citations · 7 references
Life SciencesNeurosciencePharmacologyNeurochemistryNeurodegenerationNeuropharmacologyMolecular Basis Of NeurodegenerationNeurodegeneration MechanismsNeuroprotectionNeurotransmitter MetabolismParkinson DiseaseParkinsonian DisordersDopaminergic NeurodegenerationDopaminergic Neuron DeathDopaminergic NeuronsDopaminergic NeuroprotectionParkinsonian DegenerationParkinsonian NeuroprotectionPars CompactaTyrosine Hydroxylation
The primary lesion in Parkinson's disease is the death of dopaminergic neurons in the substantia nigra. The role of cyclooxygenase (COX)-2 in the etiology of Parkinson's disease was explored using COX-2 gene knockout mice. Mortality after injection of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP, a chemical known to cause parkinsonism in humans) in heterozygous COX-2-deficient mice was lower than that in wild-type mice. The number of tyrosine hydroxylase immunoreactive neurons in the substantia nigra pars compacta of MPTP-treated wild-type mice declined to a greater extent than in heterozygous mice. Inhibition of COX-2 protein expression decreased the lesion caused by MPTP and protected the dopaminergic neurons in substantia nigra pars compacta. This result suggested that inhibition of COX-2 has potential therapeutic implications.
7
Robert Langenbach, Charles Loftin, Christopher Lee et al. · Biochemical Pharmacology · 1999 · 231 citations
Aspirin and Salicylate Protect Against MPTP‐Induced Dopamine Depletion in Mice
Nadine Aubin, O. Curet, Annie Deffois et al. · Journal of Neurochemistry · 1998 · 215 citations
Medicine, Neuroscience, Pharmacology +17